[ad_1]
Gilead Sciences announced plans to help India alleviate the shortage of remdesivir, a drug widely used to treat Covid-19, as the country experiences a historic increase in new infections.
The California-based pharmaceutical company said in a statement Monday evening that it would provide its volunteer license partners with “technical assistance,” help set up new manufacturing facilities and give a key ingredient “to quickly increase production.” remdesivir.
The company said the seven licensees in India have “significantly accelerated production” of remdesivir by increasing batch sizes, adding new manufacturing facilities and involving other contract manufacturers across the country.
Gilead said that “while these efforts are expected to increase the availability of remdesivir in the coming weeks,” it would donate at least 450,000 vials of the antiviral to India “to help alleviate the immediate need for treatment.”
Remdesivir had once been considered a wonderful drug to treat Covid-19, but the World Health Organization concluded last year that it had no significant effect on a patient’s chances of survival. However, it has been an important part of India’s efforts to treat the coronavirus.
India has recently set a record number of new coronavirus cases reported in a single day in any country and the rise in infections has put its hospital system under heavy strain. The New Delhi authorities do use prohibited of oxygen cylinders, except essential industries.
In mid-April, India blocked remdesivir exports out of concern, there would be drug shortages. Days later, more than 800 shots of the drug they were stolen of a Bhopal government hospital in the state of Madhya Pradesh, aggravating supply constraints.
Europe and the United Kingdom they are intended to intensify assistance in India. The Biden administration said Monday that the U.S. would send up Dose of 60 m of the Oxford / AstraZeneca Covid-19 vaccine abroad. While the White House did not say where the blows would go, demand from India is likely to be high.
[ad_2]
Source link
